Table 1.
Functions of m6A writers in cancer.
| m6A Enzyme system | Cancer type | Overexpressed or Underexpressed | Target(s) | Changes in the behavior of tumor cells | Reference |
|---|---|---|---|---|---|
| Wrirers | |||||
| METTL3 | lung adenocarcinoma. | Overexpressed | EGFR, TAZ, MK2, DNMT3A and BRD4 | Promote the growth, survival, and proliferation | (69–71) |
| breast carcinoma | Overexpressed | The positive feedback loop HBXIP/LET7G/HBX2P | Promote cell proliferation | (71) | |
| hepatocellular carcinoma | Overexpressed | SOCS2 | Affect the occurrence of cancer through YTHDF2-mediated degradation of m6A | (72) | |
| acute myelogenous leukemia | Overexpressed | C-MYC, BCL-2 and PTEN | Promote the survival and proliferation | (73) | |
| endometrial carcinoma | Underexpressed | AKT signaling | Promotes cell proliferation | (74) | |
| endometrial carcinoma | Underexpressed | ADAM19, EPHA3 and KLF4/CDKN2A, BRCA2 and TP53 | Promote the growth and self-renewal | (75) | |
| renal carcinoma | Underexpressed | Cell cycle | Promote cell proliferation, migration, and invasion | (76) | |
| gastric carcinoma | Overexpressed | H3K27-METTL3-HDGF-GLUT4/ENO2 | Glycolysis | (77) | |
| hepatocellular carcinoma | Underexpressed | mTOR | Glycolysis | (78) | |
| colorectal cancer | Overexpressed | HK2/SLC2A1 | Glycolysis | (77) | |
| METTL14 | pancreatic carcinoma | Overexpressed | AMPK α, ERK1/2 and mTOR signaling pathways | Promote cell apoptosis | (79) |
| acute myelogenous leukemia | Overexpressed | MYC and MYB | Promote cell proliferation | (80) | |
| breast carcinoma | Underexpressed | Promote tumor growth, angiogenesis, and tumor development | (81) | ||
| endometrial carcinoma | Underexpressed | AKT signaling | Promote cell proliferation | (82) | |
| bladder carcinoma | Underexpressed | Notch1 | Negative regulation in proliferation, metastasis, and tumor initiation | (83) | |
| WTAP | malignant glioma | Overexpressed | EGF | Oncogene | (84, 85) |
| acute myelogenous leukemia | Overexpressed | HSP90 | Regulation in abnormal proliferation and arrested differentiation | (86) | |
| renal carcinoma | Overexpressed | CDK2 | Promote cell proliferation | (87) | |
| hepatocellular carcinoma | Overexpressed | HUR-ETS1 | Promote proliferation of hepatocellular carcinoma cells in vitro and in vivo | (88) | |
| High-grade serous ovarian cancer | Overexpressed | MAPK and AKT signaling pathways | Associated with proliferation of cancer cells and lymph node metastasis | (89) |